Niagen Bioscience, Inc.
Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+)… Read more
Niagen Bioscience, Inc. (NAGE) - Net Assets
Latest net assets as of September 2025: $70.68 Million USD
Based on the latest financial reports, Niagen Bioscience, Inc. (NAGE) has net assets worth $70.68 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($98.14 Million) and total liabilities ($27.46 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $70.68 Million |
| % of Total Assets | 72.02% |
| Annual Growth Rate | 108.02% |
| 5-Year Change | 180.65% |
| 10-Year Change | 773.87% |
| Growth Volatility | 228611.11 |
Niagen Bioscience, Inc. - Net Assets Trend (2007–2024)
This chart illustrates how Niagen Bioscience, Inc.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Niagen Bioscience, Inc. (2007–2024)
The table below shows the annual net assets of Niagen Bioscience, Inc. from 2007 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $46.09 Million | +61.98% |
| 2023-12-31 | $28.46 Million | -0.75% |
| 2022-12-31 | $28.67 Million | -9.63% |
| 2021-12-31 | $31.73 Million | +93.17% |
| 2020-12-31 | $16.42 Million | -19.67% |
| 2019-12-31 | $20.45 Million | -24.77% |
| 2018-12-31 | $27.18 Million | -49.52% |
| 2017-12-31 | $53.83 Million | +439.72% |
| 2016-12-31 | $9.97 Million | +89.10% |
| 2015-12-31 | $5.27 Million | +31.92% |
| 2014-12-31 | $4.00 Million | -29.43% |
| 2013-12-31 | $5.67 Million | +41.87% |
| 2012-12-31 | $3.99 Million | +55.91% |
| 2011-12-31 | $2.56 Million | -48.11% |
| 2010-12-31 | $4.94 Million | +371.26% |
| 2009-12-31 | $1.05 Million | -40.12% |
| 2008-12-31 | $1.75 Million | +971657.22% |
| 2007-12-31 | $180.00 | -- |
Equity Component Analysis
This analysis shows how different components contribute to Niagen Bioscience, Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 18187018000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $77.00K | 0.17% |
| Other Comprehensive Income | $-4.00K | -0.01% |
| Other Components | $227.93 Million | 494.49% |
| Total Equity | $46.09 Million | 100.00% |
Niagen Bioscience, Inc. Competitors by Market Cap
The table below lists competitors of Niagen Bioscience, Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Cohen Circle Acquisition Corp. I Class A Ordinary Shares
NASDAQ:CCIR
|
$251.46 Million |
|
Lootom Telcovideo Network Wuxi Co Ltd
SHE:300555
|
$251.48 Million |
|
MGP Ingredients Inc
NASDAQ:MGPI
|
$251.48 Million |
|
Time Publishing and Media Co Ltd Class A
SHG:600551
|
$251.53 Million |
|
Dnake Xiamen Intelligent Technology
SHE:300884
|
$251.40 Million |
|
Chervon Holdings Limited
PINK:CHRHF
|
$251.40 Million |
|
Lifestyle Communities Ltd
AU:LIC
|
$251.28 Million |
|
BTQ Technologies Corp. Common Stock
NASDAQ:BTQ
|
$251.23 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Niagen Bioscience, Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 28,456,000 to 46,094,000, a change of 17,638,000 (62.0%).
- Net income of 8,550,000 contributed positively to equity growth.
- Other factors increased equity by 9,088,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $8.55 Million | +18.55% |
| Other Changes | $9.09 Million | +19.72% |
| Total Change | $- | 61.98% |
Book Value vs Market Value Analysis
This analysis compares Niagen Bioscience, Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 8.25x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 141673.40x to 8.25x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2007-12-31 | $0.00 | $4.77 | x |
| 2008-12-31 | $0.19 | $4.77 | x |
| 2009-12-31 | $0.11 | $4.77 | x |
| 2010-12-31 | $0.31 | $4.77 | x |
| 2011-12-31 | $0.11 | $4.77 | x |
| 2012-12-31 | $0.12 | $4.77 | x |
| 2013-12-31 | $0.17 | $4.77 | x |
| 2014-12-31 | $0.11 | $4.77 | x |
| 2015-12-31 | $0.15 | $4.77 | x |
| 2016-12-31 | $0.27 | $4.77 | x |
| 2017-12-31 | $1.21 | $4.77 | x |
| 2018-12-31 | $0.49 | $4.77 | x |
| 2019-12-31 | $0.36 | $4.77 | x |
| 2020-12-31 | $0.27 | $4.77 | x |
| 2021-12-31 | $0.47 | $4.77 | x |
| 2022-12-31 | $0.41 | $4.77 | x |
| 2023-12-31 | $0.38 | $4.77 | x |
| 2024-12-31 | $0.58 | $4.77 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Niagen Bioscience, Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 18.55%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 8.58%
- • Asset Turnover: 1.46x
- • Equity Multiplier: 1.48x
- Recent ROE (18.55%) is above the historical average (-1279.50%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2007 | -21323.33% | 0.00% | 0.00x | 3.22x | $-38.40K |
| 2008 | -120.31% | -46.70% | 1.10x | 2.33x | $-2.28 Million |
| 2009 | -86.65% | -15.71% | 1.62x | 3.40x | $-1.01 Million |
| 2010 | -41.56% | -27.12% | 1.16x | 1.32x | $-2.55 Million |
| 2011 | -308.24% | -97.32% | 1.29x | 2.45x | $-8.15 Million |
| 2012 | -292.05% | -100.45% | 1.29x | 2.26x | $-12.06 Million |
| 2013 | -78.01% | -43.50% | 1.13x | 1.59x | $-4.99 Million |
| 2014 | -134.76% | -35.19% | 1.33x | 2.88x | $-5.79 Million |
| 2015 | -52.54% | -15.49% | 0.95x | 3.55x | $-3.30 Million |
| 2016 | -29.36% | -13.52% | 1.10x | 1.98x | $-3.93 Million |
| 2017 | -21.14% | -53.67% | 0.34x | 1.17x | $-16.76 Million |
| 2018 | -122.58% | -105.57% | 0.75x | 1.55x | $-36.03 Million |
| 2019 | -157.24% | -69.45% | 1.15x | 1.97x | $-34.19 Million |
| 2020 | -121.32% | -33.62% | 1.54x | 2.34x | $-21.57 Million |
| 2021 | -85.50% | -40.22% | 1.17x | 1.82x | $-30.30 Million |
| 2022 | -57.69% | -22.96% | 1.33x | 1.89x | $-19.41 Million |
| 2023 | -17.35% | -5.91% | 1.52x | 1.93x | $-7.78 Million |
| 2024 | 18.55% | 8.58% | 1.46x | 1.48x | $3.94 Million |
Industry Comparison
This section compares Niagen Bioscience, Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Niagen Bioscience, Inc. (NAGE) | $70.68 Million | -21323.33% | 0.39x | $251.41 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |